During the video interview, Tara Heitner, CEO of Cyxone, also commented on the new collaboration with Dr Kalev Kask, who runs the US based contract research organization (CRO) EGeen, and what news we can expect from Cyxone in the coming months.
The interview was recorded before Cyxone’s press release that the company is initiating a clinical phase II study in Covid-19-patients, a subject that BioStock will return to.
Watch the full interview below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
